VIP · Research brief

What is Vasoactive Intestinal Peptide? (VIP Explained)

Real Peptides Research TeamEditorial

Updated April 3, 202610 min read

54 WORDS

Short answer

Research from the Karolinska Institute found that vasoactive intestinal peptide influences immune cell differentiation in ways that synthetic immunosuppressants cannot replicate. Suggesting it occupies a unique regulatory space in cellular communication. For laboratories investigating autoimmune conditions, inflammatory cascades, or neuroprotection, VIP represents one of the most versatile yet underutilized peptides in contemporary biological research.

Key takeaways

Vasoactive intestinal peptide is a 28-amino-acid neuropeptide that binds VPAC1 and VPAC2 receptors to activate cyclic AMP signaling, regulating immune function, smooth muscle tone, secretion, vasodilation, and circadian rhythms across multiple organ systems.
VIP's half-life in circulation is 1–2 minutes due to rapid enzymatic degradation by DPP-4 and NEP, creating significant challenges for therapeutic dosing and requiring continuous infusion or frequent repeated administration in experimental protocols.
In immune research, VIP shifts T-cell differentiation away from pro-inflammatory Th1 and Th17 phenotypes toward regulatory T cells while polarizing macrophages from M1 to M2, reducing cytokine production and promoting inflammation resolution.
VIP functions as the primary inhibitory neurotransmitter in the enteric nervous system, relaxing gastrointestinal smooth muscle and coordinating motility. VIP knockout mice exhibit fatal intestinal dysfunction.
Experimental autoimmune encephalomyelitis and collagen-induced arthritis models demonstrate VIP's capacity to reduce disease severity, limit inflammatory infiltrates, and preserve tissue integrity through both peripheral immune suppression and direct tissue protection.
VPAC2 receptor signaling in the suprachiasmatic nucleus synchronizes circadian rhythms. Mice lacking VIP or VPAC2 lose rhythm coherence and fail to maintain stable phase relationships under constant conditions.

At Real Peptides, we've synthesized research-grade vasoactive intestinal peptide for hundreds of laboratories pursuing diverse protocols. From gut motility studies to neuroinflammation models. The gap between understanding VIP's breadth and leveraging it experimentally comes down to three factors: receptor distribution, dose-response curves, and delivery method constraints that most peptide suppliers don't address.

What is vasoactive intestinal peptide?

Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide that functions as a neurotransmitter, hormone, and immune modulator across the central nervous system, gastrointestinal tract, cardiovascular system, and immune organs. Originally isolated from porcine small intestine in 1970, VIP binds primarily to VPAC1 and VPAC2 receptors to trigger cyclic AMP-dependent signaling cascades that regulate smooth muscle relaxation, cytokine production, circadian rhythm synchronization, and mucosal secretion.

Yes, vasoactive intestinal peptide regulates immune tolerance and inflammatory response. But not through the suppression mechanism most people assume. VIP shifts T-helper cell differentiation away from pro-inflammatory Th1 and Th17 phenotypes toward regulatory T-cell (Treg) populations, creating an immunological environment that favors resolution rather than activation. The rest of this piece covers exactly how that mechanism operates, which tissues express the highest receptor density, and what experimental constraints limit VIP's translational potential in clinical models.

The Biological Distribution and Receptor Architecture of Vasoactive Intestinal Peptide

Vasoactive intestinal peptide is expressed throughout the peripheral and central nervous systems, with particularly high concentrations in the hypothalamus, cortex, gastrointestinal tract, respiratory epithelium, and reproductive organs. Unlike peptides with narrow tissue localization, VIP operates as both a neurotransmitter released from nerve terminals and a circulating hormone secreted into the bloodstream. This dual functionality creates challenges for dose-response modeling. Systemic VIP administration produces effects that localized neural release would not, and vice versa.

VIP binds to two G-protein-coupled receptors: VPAC1 (vasoactive intestinal peptide receptor 1) and VPAC2 (vasoactive intestinal peptide receptor 2). VPAC1 is broadly distributed across the CNS, immune cells (particularly T cells and macrophages), liver, lung, and intestinal epithelium. VPAC2 shows preferential expression in smooth muscle, the suprachiasmatic nucleus (the brain's circadian pacemaker), and pancreatic beta cells. Both receptors activate adenylyl cyclase upon ligand binding, raising intracellular cyclic AMP (cAMP) levels and triggering downstream protein kinase A (PKA) signaling. The canonical pathway for VIP-mediated cellular responses.

A third receptor, PAC1 (pituitary adenylate cyclase-activating polypeptide receptor 1), binds VIP with lower affinity but still contributes to neuroprotective signaling in specific brain regions. This receptor overlap with PACAP (pituitary adenylate cyclase-activating polypeptide), a structurally related peptide, complicates experimental interpretation. Effects attributed to VIP may partly reflect PAC1 activation, particularly at higher concentrations.

The half-life of vasoactive intestinal peptide in circulation is approximately 1–2 minutes due to rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase (NEP). This extreme brevity creates significant barriers for therapeutic application. Continuous infusion or repeated dosing is required to maintain receptor occupancy, and bioavailability through non-intravenous routes remains poor. Modified analogs with extended half-lives exist in research pipelines, but none have achieved the regulatory approval or commercial availability of native VIP.

Our synthesis protocols at Real Peptides guarantee vasoactive intestinal peptide with exact amino-acid sequencing and >98% purity verified through HPLC and mass spectrometry. Every batch ships with reconstitution guidelines optimized for the peptide's stability profile. Lyophilized VIP powder remains stable at −20°C for 24 months, but once reconstituted with bacteriostatic water, it must be refrigerated at 2–8°C and used within 14 days to prevent degradation.

Mechanisms of Action: How Vasoactive Intestinal Peptide Regulates Physiology

Vasoactive intestinal peptide exerts its effects through cyclic AMP elevation following VPAC receptor activation. The resulting PKA activation phosphorylates transcription factors such as CREB (cAMP response element-binding protein), which upregulates gene expression for anti-inflammatory cytokines including IL-10 and TGF-beta while simultaneously downregulating pro-inflammatory mediators like TNF-alpha, IL-6, and IL-12. This transcriptional shift is the molecular basis for VIP's immunomodulatory properties.

In the gastrointestinal tract, VIP acts as the primary inhibitory neurotransmitter within the enteric nervous system, particularly in the myenteric plexus. It relaxes smooth muscle in the stomach, small intestine, and colon by reducing intracellular calcium availability and hyperpolarizing muscle cell membranes. This action coordinates with other inhibitory signals to regulate gastric emptying, intestinal transit time, and sphincter tone. VIP knockout mice exhibit severe gastrointestinal motility defects and fail to survive past weaning.

VIP stimulates secretion throughout the digestive and respiratory tracts. It promotes water and electrolyte secretion from intestinal epithelial cells, pancreatic acinar cells, and bronchial glands while simultaneously inhibiting gastric acid secretion in the stomach. The net effect is increased luminal hydration and mucus production. Responses that support digestion and pathogen clearance but can become pathological in conditions like cholera, where bacterial toxins hijack VIP-like signaling to cause secretory diarrhea.

In the cardiovascular system, vasoactive intestinal peptide induces vasodilation by relaxing vascular smooth muscle and stimulating nitric oxide (NO) release from endothelial cells. The resulting decrease in peripheral vascular resistance lowers blood pressure. An effect observable in experimental models but difficult to leverage therapeutically given VIP's rapid degradation. Regional blood flow increases are particularly pronounced in the gastrointestinal tract, cerebral vasculature, and reproductive organs during VIP administration.

The peptide's role in circadian rhythm regulation centers on VPAC2 receptor signaling in the suprachiasmatic nucleus (SCN), the brain region that synchronizes daily biological rhythms with environmental light-dark cycles. VIP-producing neurons within the SCN coordinate firing patterns across the neuronal network, maintaining rhythm stability and phase coherence. Mice lacking functional VIP or VPAC2 receptors exhibit fragmented circadian rhythms and lose synchronization under constant darkness.

At Real Peptides, laboratories studying VIP's chronobiological effects use our VIP with precise reconstitution protocols that preserve peptide integrity across experimental timelines. Small-batch synthesis ensures consistency across study cohorts. A critical factor when circadian endpoints require weeks of repeated dosing.

Vasoactive Intestinal Peptide in Immune Regulation and Inflammation Research

Vasoactive intestinal peptide shifts immune cell behavior toward anti-inflammatory, pro-resolution phenotypes through multiple mechanisms. In dendritic cells, VIP reduces expression of co-stimulatory molecules (CD80, CD86) and MHC class II, impairing their ability to activate naive T cells. This creates a tolerogenic antigen-presenting environment that favors regulatory T-cell induction over effector T-cell priming.

VIP directly modulates T-cell differentiation. It inhibits Th1 polarization by suppressing IFN-gamma production and downregulating the transcription factor T-bet. Th17 differentiation is similarly constrained through reduced IL-17A synthesis and RORgammaT expression. Simultaneously, VIP promotes Treg expansion by upregulating Foxp3, the master transcription factor for regulatory T cells, and enhancing IL-10 secretion. These Tregs actively suppress effector T-cell responses and dampen inflammation in target tissues.

Macrophage polarization shifts from M1 (pro-inflammatory) to M2 (anti-inflammatory, tissue-remodeling) phenotypes under VIP exposure. M1 markers including inducible nitric oxide synthase (iNOS) and TNF-alpha decrease, while M2 markers such as arginase-1 and IL-10 increase. This phenotype switch accelerates inflammation resolution and promotes tissue repair in injury models.

Experimental autoimmune encephalomyelitis (EAE), the murine model for multiple sclerosis, has generated substantial VIP research. Daily VIP administration during disease induction reduces clinical severity scores, limits CNS inflammatory infiltrates, and decreases demyelination. The mechanism involves both peripheral immune suppression (reduced Th1/Th17 trafficking to the CNS) and direct neuroprotection (reduced microglial activation and preserved oligodendrocyte survival). Similar efficacy has been demonstrated in collagen-induced arthritis models, where VIP reduces joint inflammation, cartilage destruction, and bone erosion.

Sepsis models reveal VIP's capacity to modulate overwhelming inflammatory responses. In LPS-induced endotoxemia, VIP pretreatment reduces serum TNF-alpha and IL-6 levels, prevents multi-organ failure, and improves survival rates. The protective effect depends on VPAC1 receptor signaling on macrophages and monocytes. Antibody blockade of VPAC1 abolishes the benefit.

Real Peptides supplies vasoactive intestinal peptide for immunology laboratories investigating cytokine networks, T-cell subset dynamics, and inflammatory disease models. Our peptide maintains activity across freeze-thaw cycles when stored correctly. A practical consideration for multi-week protocols requiring intermittent dosing. Researchers studying peptide-based immune modulation often pair our VIP with Thymosin Alpha 1 Peptide or Thymalin to compare mechanistic pathways across different immune-regulating molecules.

Vasoactive Intestinal Peptide: Research Applications Comparison

Research Model	Primary VIP Mechanism	Expected Outcome Markers	Experimental Considerations	Bottom Line
Autoimmune disease (EAE, CIA)	Treg induction, Th1/Th17 suppression via VPAC1	Reduced disease severity scores, decreased CNS infiltrates, lower joint inflammation	Requires daily dosing during disease induction; half-life necessitates continuous presence during immune priming	VIP demonstrates consistent efficacy across autoimmune models but short half-life limits translational feasibility without analog development
Sepsis/endotoxemia	Macrophage M1-to-M2 polarization, reduced TNF-alpha/IL-6	Improved survival, lower serum cytokines, preserved organ function	Timing relative to LPS challenge is critical. Pretreatment more effective than post-treatment	VIP shows promise in early intervention scenarios but therapeutic window is narrow in acute inflammatory settings
Gastrointestinal motility	Smooth muscle relaxation via cAMP/PKA, reduced intracellular calcium	Delayed gastric emptying, increased intestinal transit time	Dose-response is biphasic. Low doses stimulate secretion, high doses inhibit motility	VIP remains the gold standard for enteric nervous system research but route of administration significantly affects regional distribution
Circadian rhythm disruption	VPAC2-mediated SCN synchronization	Restored rhythm coherence, normalized phase angle	Long-term protocols require stable dosing schedules; mice lacking VIP provide strong genetic controls	VIP is irreplaceable in circadian neuroscience but experimental design must account for its rapid clearance
Neuroprotection (ischemia, excitotoxicity)	Reduced microglial activation, enhanced BDNF expression	Decreased infarct volume, preserved neuronal density	Blood-brain barrier penetration is limited; intracerebroventricular delivery often required	VIP shows neuroprotective capacity in injury models but delivery constraints reduce clinical translation potential

What If: Vasoactive Intestinal Peptide Scenarios

What If VIP Is Administered After the Inflammatory Response Has Already Peaked?

Administer VIP during the resolution phase rather than the initiation phase. Its efficacy shifts from prevention to repair. Post-peak VIP still promotes M2 macrophage polarization and Treg expansion, which accelerates inflammation resolution and tissue remodeling. Sepsis models show reduced efficacy when VIP is given after cytokine surge, but chronic inflammation models (arthritis, colitis) demonstrate benefit even when treatment begins after disease establishment. The therapeutic window narrows as the inflammatory cascade matures.

What If the Research Protocol Requires Oral or Intranasal Delivery Instead of Injection?

Oral bioavailability of native vasoactive intestinal peptide is essentially zero. The peptide is degraded by gastric acid and intestinal proteases before systemic absorption occurs. Intranasal delivery achieves limited CNS penetration through olfactory pathways, bypassing the blood-brain barrier partially, but systemic exposure remains minimal. Modified analogs with protease resistance or absorption enhancers can improve non-injectable delivery, but these are experimental and not commercially standardized. For reliable systemic or CNS effects, subcutaneous or intravenous administration remains necessary.

What If VIP Concentration in Reconstituted Solution Appears Lower Than Expected?

Verify storage temperature immediately. Exposure above 8°C causes progressive degradation even in lyophilized form, and reconstituted VIP degrades faster at room temperature. If the vial was stored correctly, the issue may be incomplete reconstitution. VIP requires gentle swirling, not vortexing, and full dissolution can take 5–10 minutes. Use bacteriostatic water, not saline, to prevent aggregation. If degradation is confirmed, discard the vial. Degraded peptide produces inconsistent results and cannot be rescued.

What If the Experimental Model Requires Multi-Week VIP Exposure?

Plan for daily injections due to VIP's 1–2 minute half-life. No depot formulation exists for native VIP. Prepare aliquots of reconstituted peptide in single-use volumes to minimize freeze-thaw cycles, which denature the peptide. Consider using osmotic minipumps for continuous subcutaneous delivery if the protocol tolerates surgical implantation. This maintains stable plasma levels and reduces handling stress in animal models. Budget for higher peptide volumes than acute protocols require.

The Mechanistic Truth About Vasoactive Intestinal Peptide

Here's the honest answer: vasoactive intestinal peptide is one of the most pleiotropic molecules in mammalian physiology, but that versatility is also its greatest limitation for therapeutic translation. The same receptor promiscuity that allows VIP to regulate immune cells, smooth muscle, neurons, and epithelial tissue simultaneously creates off-target effects that cannot be separated by dose adjustment. You cannot achieve gut-specific motility modulation without affecting vascular tone, and you cannot target CNS inflammation without systemic immune suppression.

The half-life problem is not a minor inconvenience. It is the central barrier to clinical application. A peptide that disappears from circulation in two minutes cannot maintain receptor occupancy long enough to shift transcriptional programs or sustain signaling cascades that depend on prolonged cAMP elevation. Continuous infusion is impractical outside critical care settings, and modified analogs with extended half-lives introduce new pharmacological variables that complicate regulatory approval.

VIP's greatest research value lies in mechanistic studies where its broad activity profile illuminates pathway interactions that single-target molecules obscure. It reveals how immune regulation, vascular control, and neural signaling intersect. Insights that inform drug design even when VIP itself does not become the drug. For laboratories studying these intersections, native VIP remains the gold standard reference compound.

Vasoactive intestinal peptide occupies a unique position in peptide research. Indispensable for understanding complex physiological networks but constrained by pharmacokinetic realities that limit its direct therapeutic application. The research continues not because VIP will become a blockbuster drug, but because the biology it uncovers guides the next generation of immune modulators, motility agents, and neuroprotective therapies. That exploratory work requires peptides synthesized with precision and delivered with stability guarantees that match the rigor of the science itself.

Real Peptides provides research-grade vasoactive intestinal peptide with the purity and consistency that multi-week protocols demand. Every batch undergoes third-party verification, and reconstitution protocols are tailored to VIP's degradation profile. Not generic peptide handling guidelines. Laboratories investigating immune modulation, enteric signaling, or neuroprotection can access our full peptide collection to compare VIP's mechanisms with structurally distinct molecules like Selank Amidate Peptide, Semax Amidate Peptide, or Thymosin Alpha 1 across experimental models. The difference between reproducible findings and inconsistent data often comes down to peptide quality at the synthesis stage. Not protocol design or model selection.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Vasoactive intestinal peptide shifts immune cell differentiation rather than broadly suppressing immune function. It promotes regulatory T-cell (Treg) expansion and M2 macrophage polarization while reducing Th1 and Th17 pro-inflammatory phenotypes through VPAC receptor-mediated cAMP signaling. Traditional immunosuppressants like corticosteroids or calcineurin inhibitors block immune activation globally, increasing infection risk, whereas VIP preserves immune competence while redirecting responses toward resolution and tolerance. This mechanistic distinction makes VIP valuable for studying selective immune modulation in autoimmune and inflammatory disease models.

No, peripherally administered vasoactive intestinal peptide does not cross the intact blood-brain barrier in significant quantities due to its hydrophilic structure and rapid enzymatic degradation. CNS effects observed in experimental models typically require intracerebroventricular injection, intranasal delivery (which provides limited olfactory pathway access), or blood-brain barrier disruption. VIP produced endogenously within the CNS by neurons acts locally as a neurotransmitter, but systemic administration does not replicate this central signaling under normal physiological conditions.

Lyophilized vasoactive intestinal peptide powder should be stored at −20°C and remains stable for 24 months. Once reconstituted with bacteriostatic water, store the solution at 2–8°C (refrigerated) and use within 14 days to prevent degradation. Avoid freeze-thaw cycles of reconstituted peptide, as repeated temperature fluctuations denature the protein structure. Prepare single-use aliquots if the protocol requires multiple dosing events. Any temperature excursion above 8°C accelerates degradation — VIP exposed to room temperature for more than 2–3 hours should be discarded.

Vasoactive intestinal peptide has a circulating half-life of only 1–2 minutes because it is rapidly degraded by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase (NEP), enzymes present in plasma and vascular endothelium. These proteases cleave peptide bonds within VIP’s amino acid sequence, rendering the molecule inactive before it can exert prolonged receptor activation. This extreme brevity creates challenges for therapeutic application and requires continuous infusion or frequent repeated dosing to maintain effective plasma concentrations in experimental protocols.

Vasoactive intestinal peptide and PACAP (pituitary adenylate cyclase-activating polypeptide) share structural similarity and both activate VPAC1 and VPAC2 receptors, but PACAP binds with much higher affinity to the PAC1 receptor, which is densely expressed in neurons. PACAP demonstrates stronger neuroprotective effects in ischemia and excitotoxicity models due to this preferential PAC1 activation, which triggers anti-apoptotic signaling and neurotrophic factor release. VIP provides neuroprotection primarily through immune modulation (reduced microglial activation) rather than direct neuronal survival signaling, making PACAP the preferred choice for acute neuronal injury studies while VIP excels in neuroinflammation models.

In vitro immune cell assays typically use vasoactive intestinal peptide concentrations ranging from 10^-9 M to 10^-7 M (1 nM to 100 nM) to activate VPAC receptors and shift cytokine production or T-cell differentiation. Lower concentrations (1–10 nM) suffice for receptor binding and cAMP elevation, while higher concentrations (50–100 nM) are used to achieve maximal transcriptional responses in primary human or murine immune cells. Concentrations above 10^-6 M can trigger non-specific effects or receptor desensitization. Dose-response curves should be established for each cell type and readout.

Vasoactive intestinal peptide is rapidly degraded in serum-containing media due to proteases including DPP-4 and NEP present in fetal bovine serum. For in vitro experiments requiring sustained VIP exposure, use serum-free or serum-reduced media, or add protease inhibitors specific to DPP-4 and NEP. Alternatively, replace VIP every 4–6 hours during long-term culture assays to maintain receptor activation. Lyophilized VIP remains stable at −20°C, but once added to culture media, expect significant degradation within 30–60 minutes unless protease activity is controlled.

VPAC1 and VPAC2 are both G-protein-coupled receptors that activate adenylyl cyclase and raise intracellular cAMP upon vasoactive intestinal peptide binding, but their tissue distribution and physiological roles differ. VPAC1 is broadly expressed on immune cells, smooth muscle, and epithelium, mediating VIP’s immunomodulatory and secretory effects. VPAC2 shows preferential expression in the suprachiasmatic nucleus (circadian pacemaker), pancreatic beta cells, and certain smooth muscle beds, regulating circadian rhythm synchronization and insulin secretion. Receptor-selective agonists exist for research purposes, allowing separation of VPAC1-mediated immune effects from VPAC2-mediated metabolic or chronobiological effects.

Yes, vasoactive intestinal peptide can be combined with other immunomodulatory peptides in research protocols to compare or synergize mechanisms. VIP is often paired with thymosin alpha-1 (which enhances Th1 responses and dendritic cell maturation) to study opposing immune polarization effects, or with regulatory peptides like alpha-MSH (which also promotes M2 macrophage polarization) to assess additive anti-inflammatory capacity. Combination studies require careful dose optimization and timeline coordination, as VIP’s short half-life may necessitate more frequent dosing than longer-acting peptides. No pharmacokinetic interactions are documented, but receptor crosstalk and signaling pathway overlap should be considered when interpreting results.

Vasoactive intestinal peptide is the primary inhibitory neurotransmitter in the enteric nervous system, coordinating smooth muscle relaxation, sphincter control, and secretion throughout the gastrointestinal tract. VIP knockout mice exhibit severe gastrointestinal motility defects and fail to survive past weaning, demonstrating its non-redundant role. Unlike acetylcholine or substance P, which mediate excitatory signals, VIP provides the counterbalancing inhibition necessary for coordinated peristalsis and gut function. No other neurotransmitter replicates VIP’s enteric signaling profile, making it irreplaceable in motility research and gastrointestinal neuroscience.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA